Page last updated: 2024-11-12

ceruletide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Ceruletide: A specific decapeptide obtained from the skin of Hila caerulea, an Australian amphibian. Caerulein is similar in action and composition to CHOLECYSTOKININ. It stimulates gastric, biliary, and pancreatic secretion; and certain smooth muscle. It is used in paralytic ileus and as diagnostic aid in pancreatic malfunction. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ceruletide : A decapeptide comprising 5-oxoprolyl, glutamyl, aspartyl, O-sulfotyrosyl, threonyl, glycyl, tryptopyl, methionyl, aspartyl and phenylalaninamide residues in sequence. Found in the skins of certain Australian amphibians, it is an analogue of the gastrointestinal peptide hormone cholecystokinin and stimulates gastric, biliary, and pancreatic secretion. It is used in cases of paralysis of the intestine (paralytic ileus) and as a diagnostic aid in pancreatic malfunction. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID16129675
CHEMBL ID1201355
CHEBI ID59219
SCHEMBL ID29520
MeSH IDM0003135

Synonyms (42)

Synonym
ceruletidum
CHEBI:59219 ,
ceruletida
CHEMBL1201355
cerulein
5-oxo-l-prolyl-l-glutaminyl-l-aspartyl-l-tyrosyl-l-threonylglycyl-l-tryptophyl-l-methionyl-l-aspartylphenyl-l-alaninamide 4-(hydrogen sulfate) (ester)
ceruletidum [inn-latin]
ceruletide [usan:inn:ban]
ccris 3063
5-oxo-l-prolyl-l-glutaminyl-l-alpha-aspartyl-o-sulfo-l-tyrosyl-l-threonylglycyl-l-tryptophyl-l-methionyl-l-alpha-aspartyl-l-phenylalaninamide
ceruletida [inn-spanish]
ceruletide (usan/inn)
17650-98-5
D03442
caerulein
ceruletide
DB00403
5-oxo-l-prolyl-l-glutaminyl-l-a-aspartyl-o-sulfo-l-tyrosyl-l-threonylglycyl-l-tryptophyl-l-methionyl-l-a-aspartyl-l-phenylalaninamide
fi-6934
888y08971b ,
unii-888y08971b
pglu-gln-asp-tyr(so3h)-thr-gly-trp-met-asp-phe-nh2
ceruletide [inn]
ceruletide [usan]
ceruletide [who-dd]
ceruletide [mart.]
5-oxo-l-prolyl-l-glutaminyl-l-a-aspartyl-o-sulfo-l-tyrosyl-l-threonylglycyl-l-tryptophyl-l-methionyl-l-.alpha.-aspartyl-l-phenylalaninamide
ceruletide [mi]
gtpl7589
SCHEMBL29520
HY-A0190
CS-5876
DTXSID8040434
caerulein, sulfated
mfcd00076478
(3s)-3-{[(1s)-1-carbamoyl-2-phenylethyl]carbamoyl}-3-[(2s)-2-[(2s)-2-{2-[(2s,3r)-2-[(2s)-2-[(2s)-2-[(2s)-4-carbamoyl-2-{[(2s)-5-oxopyrrolidin-2-yl]formamido}butanamido]-3-carboxypropanamido]-3-[4-(sulfooxy)phenyl]propanamido]-3-hydroxybutanamido]acetamido
AKOS030529560
Q5065299
C73362
AS-56061
fi-6934caerulein
EN300-23248418

Research Excerpts

Overview

Ceruletide is a synthetic decapeptide closely resembling the 8-carboxy-terminal peptide of cholecystokinin (CCK-8) with which it shares several biological properties.

ExcerptReferenceRelevance
"Ceruletide is a decapeptide isolated from the skin of an Australian frog. "( Ceruletide analgesia in biliary colic.
Celotti, F; De Paolis, C; Pardo, A, 1984
)
3.15
"Ceruletide appears to be a novel and practical treatment that can substantially alleviate the symptoms of dyskinesia."( Treatment of tardive dyskinesia with ceruletide: a double-blind, placebo-controlled study.
Kojima, T; Koshino, Y; Miyasaka, M; Nakane, Y; Shimazono, Y; Takahashi, R; Yagi, G; Yamauchi, T, 1992
)
1.28
"Ceruletide is a synthetic decapeptide closely resembling the 8-carboxy-terminal peptide of cholecystokinin (CCK-8) with which it shares several biological properties. "( Ineffectiveness of ceruletide to reduce food intake and body weight in obese women hospitalized for weight reduction and treated with a restricted diet. A double-blind study.
Alberetto, M; Calderara, A; Cavagnini, F; Danesi, L; De Paolis, C; Farina, R; Magella, A; Pontiroli, AE,
)
1.9

Effects

ExcerptReferenceRelevance
"Ceruletide has been demonstrated to be rarely accompanied by a few minor side effects, to have a cholecystokinetic effect more rapid and intense than fatty meal and cholecystokinine and to be followed by frequent diagnostic visualization of cystic duct and choledochus."( [Cholecystography with ceruletide. Results and evaluation of its routine use].
Colagrande, C; Colosimo, C; Santini, A; Vecchioli, A,
)
1.16

Treatment

Post-treatment with ceruletide (0.03 mg/kg) 3 h after each methamphetamine accelerated, whereas such post-treatment as haloperidol delayed the induction of methamphetamine sensitization.

ExcerptReferenceRelevance
"With ceruletide treatment, the power values of the frontal EEGs increased in the whole bands but only in the first week."( Effects of ceruletide on clinical symptoms and EEGS in schizophrenia.
Habu, K; Mizuki, Y; Nakamura, K; Ushijima, I; Yamada, M, 1988
)
1.12
"Post-treatment with ceruletide (0.03 mg/kg) 3 h after each methamphetamine accelerated, whereas such post-treatment with ceruletide (0.1 mg/kg) or haloperidol (0.03-0.3 mg/kg) delayed, the induction of methamphetamine sensitization."( Contrasting effects on methamphetamine sensitization of ceruletide, a cholecystokinin-like decapeptide, and haloperidol.
Kuribara, H, 1995
)
0.85
"Pretreatment with ceruletide (40 micrograms/100 g b."( Barrel rotation in rats induced by SMS 201-995: suppression by ceruletide.
Imura, H; Ishikawa, Y; Murakami, Y; Shimatsu, A, 1990
)
0.84

Toxicity

ExcerptReferenceRelevance
" In therapeutic doses the adverse effects noted are mild, transient extensions of the drug's pharmacologic actions and are manifest as nausea, vomiting, abdominal pain, and rarely hypotension and tachycardia."( Pharmacology, clinical uses, and adverse effects of ceruletide, a cholecystokinetic agent.
Robbins, AH; Vincent, ME; Wetzner, SM,
)
0.38

Compound-Compound Interactions

ExcerptReferenceRelevance
"The protein compositions of pig pancreatic secretions collected under stimulation by secretin alone or in combination with caerulein were compared by SDS polyacrylamide gel electrophoresis."( Different patterns of proteins are secreted by the pig pancreas when stimulated by secretin alone or in combination with caerulein.
Beaudoin, AR; LeBel, D, 1985
)
0.27

Bioavailability

ExcerptReferenceRelevance
" In these procedures, the reduced insulin bioavailability was associated with a reduction in caerulein- and vasoactive intestinal polypeptide-stimulated enzyme release, which was shown as a reduction of maximum responsiveness to caerulein without alteration of sensitivity."( Activity of the insulo-acinar axis in the isolated perfused rat pancreas.
Bruzzone, R; Gjinovci, A; Renold, AE; Trimble, ER, 1985
)
0.27
" These results indicate that FK480 is a potent, competitive, and specific CCK receptor antagonist on the exocrine pancreas in vivo, having oral bioavailability and a long biological half-life."( Effects of a new benzodiazepine derivative cholecystokinin receptor antagonist FK480 on pancreatic exocrine secretion in anesthetized rats.
Otsuki, M; Tachibana, I, 1994
)
0.29
" These results suggest that the half-life of loxiglumide given by oral route is longer than that by sc route or that the bioavailability of oral loxiglumide is higher than that of sc dose."( Duration and potency of anticholecystokinin action of subcutaneous and oral loxiglumide on cerulein-stimulated pancreatic exocrine secretion.
Otsuki, M; Watanabe, N, 1993
)
0.29
" Oral administration of compounds 14a and 15a also produced a lasting antagonism to the hypomotility induced by CCK-8 in mice, suggesting a good bioavailability and metabolic stability."( 5-(Tryptophyl)amino-1,3-dioxoperhydropyrido[1,2-c]pyrimidine-based potent and selective CCK(1) receptor antagonists: structural modifications at the tryptophan domain.
Ballaz, S; Bartolomé-Nebreda, JM; Cenarruzabeitia, E; Del Río, J; García-López, MT; Gómez-Monterrey, I; González-Muñiz, R; Herranz, R; LaTorre, M; Martín-Martínez, M, 1999
)
0.3
" We have investigated the effect of AZD8309, a potent and orally bioavailable antagonist of the chemokine receptor CXCR2, which has been proposed to regulate the transmigration of neutrophils."( Effect of oral administration of AZD8309, a CXCR2 antagonist, on the severity of experimental pancreatitis.
D'Haese, J; Günther, A; Hansen, MB; Kärrman Mårdh, C; Lerch, MM; Mahajan, UM; Malla, SR; Mayerle, J; Sendler, M; Weiss, FU,
)
0.13
" We hypothesized that rectal administration of Tac would effectively mitigate PEP by ensuring systemic and pancreatic bioavailability of Tac."( Rectal administration of tacrolimus protects against post-ERCP pancreatitis in mice.
Barakat, MT; Bottino, R; Ding, Y; Frymoyer, AR; Husain, SZ; Jayaraman, T; Khalid, A; Lin, YC; Murayi, JA; Ni, J; Papachristou, GI; Poropatich, R; Sheth, SG; Swaminathan, G; Tsai, CY; Wen, L; Yu, M, 2023
)
0.91

Dosage Studied

An investigation was undertaken to test whether the dose-response curve of a cholecystokinin-like agent (ceruletide) could be established by administering it in graded doses sequentially on the same day. No obvious dose- response relationship was observed in either intensity or duration of inhibitory action of ceruletide.

ExcerptRelevanceReference
" From dose-response curves it appears that, on a molar basis, the potency of secretin was 20 times higher than that of VIP."( In vitro interactions of gastrointestinal hormones on cyclic adenosine 3':5'-monophosphate levels and amylase output in the rat pancreas.
Christophe, J; De Neef, P; Deschodt-Lanckman, M; Labrie, F; Robberecht, P, 1975
)
0.25
" The dose-response curves for these three effects of bombesin were very similar, with effects being detectable at concentrations of about 30 pM and maximal effects at about 10 nM."( In vitro action of bombesin on amylase secretion, membrane potential, and membrane resistance in rat and mouse pancreatic acinar cells. A comparison with other secretagogues.
Iwatsuki, N; Petersen, OH, 1978
)
0.26
"The effect of somatostatin on the pancreatic exocrine response to different doses of exogenous stimuli and the somatostatin dose-response relationships on pancreatic secretion were studied in conscious dogs."( Inhibition of exocrine pancreatic secretion by somatostatin in dogs.
Bommelaer, G; Esteve, JP; Ribet, A; Susini, C; Vaysse, N, 1978
)
0.26
"3 These peptide secretagogues were divided into the gastrin group and the CCK-PZ group according to the time course of the depolarizations and the shape of the dose-response curve."( The effects of gastrin and gastrin analogues on pancreatic acinar cell membrane potential and resistance.
Iwatsuki, N; Kato, K; Nishiyama, A, 1977
)
0.26
" Dose-response analysis showed that maximal bicarbonate response to motilin was about 5% of that to secretin and maximal protein response was about 35% of that to caerulein."( Effect of motilin on pancreatic secretion.
Dembiński, A; Konturek, SJ; Król, R; Wünsch, E, 1976
)
0.26
" Dose-response analysis showed that maximal bicarbonate response to VIP was about 17% of that to secretin."( Comparison of secretin and vasoactive intestinal peptide on pancreatic secretion in dogs.
Dembinski, A; Konturek, SJ; Krol, R; Thor, P, 1975
)
0.25
" in cats produced superimposable pancreatic dose-response curves for volume flow and bicarbonate secretion, reaching almost identical observed and maximal calculated outputs with both peptides."( Comparison of vasoactive intestinal peptide and secretin in stimulation of pancreatic secretion.
Konturek, SJ; Pucher, A; Radecki, T, 1976
)
0.26
" To investigate the secretory response of these substances, and to construct dose-response curves 10-day-old conscious rats were given subcutaneously a single injection of caerulein, secretin, caffeine or the combination of these compounds (caerulein + secretin, caerulein + caffeine)."( Secretin potentiates, caffeine does not affect caerulein--stimulated pancreatic enzyme depletion and growth in newborn rats.
Ammann, RW; Dobronyl, I; Papp, M; Varga, G, 1990
)
0.28
" In animals dosed daily for 2 or 3 days, the number of head twitches at 24 h after the last dose was about one-third of the number before treatment."( Long-lasting effect of ceruletide on dyskinesia and monoaminergic neuronal pathways in rats treated with iminodipropionitrile.
Asanuma, M; Haba, K; Mori, A; Ogawa, N, 1991
)
0.59
" CLN and CCK-8 was found to have a complex effect on the acetylcholine and choline contents depending on the brain region, dosage and treatment time."( Effects of caerulein and cholecystokinin-octapeptide on acetylcholine and choline contents in the brains of intact and vagotomized mice.
Miyate, H, 1990
)
0.28
" Acini preexposed to concentrations of carbamylcholine of 10(-6) M or greater showed shifts to the right in the subsequent carbamylcholine dose-response curves of amylase release."( Short-term cholinergic desensitization of rat pancreatic secretory response.
Asselin, J; Larose, L; Morisset, J, 1987
)
0.27
" Subcutaneous injections of 20 micrograms/kg body weight of caerulein induced a significant increase in serum amylase activity and histologic evidence of acute interstitial pancreatitis similar to those observed with the 50 micrograms/kg body weight dosage of caerulein."( Histologic and biochemical alterations in experimental acute pancreatitis induced by supramaximal caerulein stimulation.
Baba, S; Fujii, M; Itoh, H; Nakamura, T; Oka, T; Otsuki, M; Tani, S,
)
0.13
" The caerulein dose-response curve was gradually shifted to the right by increasing doses of CR 1409, indicating competitive-like kinetics."( Comparative effects of CCK receptor antagonists on rat pancreatic secretion in vivo.
Grendell, JH; Niederau, C; Niederau, M; Strohmeyer, G, 1989
)
0.28
" Studies in vitro dispersed rat pancreatic acini showed that GRF added to the incubation medium of these acini caused an increase in basal amylase release and shifted to the left the amylase dose-response curve to caerulein and urecholine but failed to affect the amylase response to VIP."( Effects of growth hormone releasing factor on pancreatic secretion in vivo and in vitro.
Bilski, J; Jaworek, J; Konturek, SJ; Mochizuki, T; Yanaihara, C; Yanaihara, N, 1989
)
0.28
" The dose-response relationships for somatostatin release and inhibition of aminopyrine uptake were similar."( Inhibition of acid formation and stimulation of somatostatin release by cholecystokinin-related peptides in rabbit gastric glands.
Bengtsson, P; Lundqvist, G; Nilsson, G, 1989
)
0.28
" Dose-response quantitative generalization was obtained by using 1 and 2 micrograms/kg caerulein."( Neuroleptic-like properties of cholecystokinin analogs: distinctive mechanisms underlying similar behavioral profiles depending on the route of administration.
De Witte, P; Gewiss, M; Roques, B; Vanderhaeghen, JJ,
)
0.13
" The dose-response curves of pancreatic juice, protein, amylase, and trypsinogen for cerulein and carbamylcholine were biphasic in both control and diabetic rats."( Effect of diabetes mellitus on pancreatic exocrine secretion from isolated perfused pancreas in rats.
Baba, S; Ohki, A; Okabayashi, Y; Otsuki, M; Suehiro, I, 1988
)
0.27
" The dose-response curve of caerulein showed the denervated pancreas as sensitive as the intact gland."( Exocrine pancreatic function in dogs with denervated pancreas.
Barthel, M; Köhler, H; Nustede, R; Schafmayer, A, 1987
)
0.27
" Atropine sulfate (10(-6) M) slightly but significantly reduced CCK-OP (10(-11) M-3 X 10(-7) M) induced contractions and the dose-response curve for CCK-OP was shifted to the right of the muscle strips of the human gallbladders."( Effects of cholecystokinin-octapeptide on the human gallbladder both in vivo and in vitro.
Ishikawa, Y; Kantoh, M; Takahashi, T; Utsunomiya, J; Yamamura, T, 1986
)
0.27
" However, no obvious dose-response relationship was observed in either intensity or duration of inhibitory action of ceruletide."( A behavioral pharmacological study on CCK-8 related peptides in mice.
Hagino, Y; Moroji, T, 1986
)
0.48
" The calcium dose-response curve paralleled those of lipase and chymotrypsin outputs."( Action of pirenzepine, a new muscarinic antagonist drug, on human pancreatic secretion.
Laugier, R; Nishimura, S; Sarles, H, 1985
)
0.27
" at a dosage 1000 times lower than that of morphine on a molar basis."( Comparative study on the electrophysiological responses at thalamic level to different analgesic peptides.
Biella, G; Braga, PC; Fraschini, F; Guidobono, F; Pecile, A; Tiengo, M, 1985
)
0.27
" Tremorolytic potency (ED50) was calculated from dose-response curves."( Cholecystokinin octapeptide (CCK-8), ceruletide and analogues of ceruletide: effects on tremors induced by oxotremorine, harmine and ibogaine. A comparison with prolyl-leucylglycine amide (MIF), anti-Parkinsonian drugs and clonazepam.
Zetler, G, 1983
)
0.54
" Patients treated with Ceruletide (n = 30, dosage of Ceruletide 2 ng/kg/min."( [Treatment of intestinal atony following gynecologic operations. Study on the effectiveness and tolerance of ceruletide].
Baur, M; Heinrich, D; Kubli, F; Schmid, H; Schulz-Wendtland, R; von Fournier, D, 1984
)
0.79
"An investigation was undertaken to test whether the dose-response curve of a cholecystokinin-like agent (ceruletide) could be established by administering it in graded doses sequentially on the same day."( A new scintigraphic technique for cholecystokinin gallbladder dose-response study: validation in rabbits.
Bobba, VR; Krishnamurthy, GT; Langrell, K; Turner, FE,
)
0.35
" Similar effects were observed on guinea-pig "in vitro" stomach preparation where PM2 and Papaverine were ineffective in modifying Histamine dose-response curves and PM3 reduced significantly maximal peak effects of Histamine, behaving as a non-competitive antagonist."( [Pharmacological actions of alkylaminoalkyl-phenylbenzisothazole compounds on the gastrointestinal tract].
Barocelli, E; Bordi, F; Chiavarini, M; Impicciatore, M; Morini, G; Plazzi, P, 1984
)
0.27
" The ability of enkephalin to relax caerulein-induced contractions and the manner in which the caerulein dose-response curve was shifted in the presence of enkephalin strongly suggest that enkephalin and caerulein are functional antagonists in this system."( Interaction of enkephalin and caerulein on guinea pig small intestine.
Lingle, PF; Yau, WM; Youther, ML, 1983
)
0.27
" Likewise, the study revealed the excellent tolerability of the test drug at the dosage employed."( Usefulness of caerulein in the treatment of post-operative intestinal atony.
Aznar García, E; Ferreira Montero, V; Martínez Laganga, A, 1980
)
0.26
" In either type of experiment the dose-response lines of naloxone against caerulein were very shallow as compared with those against morphine."( Caerulein and morphine: an attempt to differentiate their antinociceptive effects.
Zetler, G, 1982
)
0.26
"caerulein administered by slow intravenous infusion at increasing dosage rates (0."( Effects of Caerulein on exocrine pancreatic secretion in sheep.
Belloli, C; Beretta, C; Faustini, R; Invernizzi, A; Ormas, P, 1981
)
0.26
" In contrast, serum amylase and light microscopy reflected a degree of pancreatitis in a close dose-response pattern to the administered cerulein dose."( Energy metabolism in mouse pancreas in response to different dosages of a CCK analogue.
Ferrell, LD; Grendell, JH; Lüthen, RE; Niederau, C, 1995
)
0.29
" After sacrifice, acini were prepared, and amylase dose-response curves to carbamylcholine (Cch) and secretin were established."( Alterations of pancreatic amylase secretion in the reserpinized rat model of cystic fibrosis. Effects of cerulein and EGF.
Benrezzak, O; Bérubé, FL; Morisset, J; Vanier, M, 1994
)
0.29
" In dispersed acini, supramaximal cerulein concentrations induced NO release, but the amylase dose-response curve was not modified by NO inhibition."( Nitric oxide modulates pancreatic basal secretion and response to cerulein in the rat: effects in acute pancreatitis.
Guarner, F; Malagelada, JR; Molero, X; Mourelle, M; Puig, V; Salas, A, 1995
)
0.29
" We have therefore evaluated the amino acid consumption test by examining the dose-response relation among increasing doses of cerulein and plasma amino acids compared with the release of pancreatic polypeptide in six healthy volunteers and six patients with severe pancreatic insufficiency proven by a pathological para-aminobenzoic acid test."( Cerulein-induced changes in plasma amino acid concentrations are not a valid test for pancreatic insufficiency.
Borovicka, J; Fried, M; Remy, B; Schwizer, W, 1995
)
0.29
" There was no dose-response relationship between CCK and plasma amino acids in either group."( Cerulein-induced changes in plasma amino acid concentrations are not a valid test for pancreatic insufficiency.
Borovicka, J; Fried, M; Remy, B; Schwizer, W, 1995
)
0.29
" Caerulein (1-100 nM), a CCK receptor agonist, caused a rightward shift of the glutamate dose-response curve."( CCKB receptor activation reduces glutamate-induced depolarization in slices of rat cerebral cortex.
Harro, J; Oreland, L; Westerling, P, 1993
)
0.29
" The antagonism produced by FK480 was competitive in nature because intraduodenal as well as intravenous infusion of FK480 (50-250 nmol/kg/hr) caused a parallel rightward shift of the entire dose-response curve for cerulein-stimulated pancreatic exocrine secretion without altering the maximal increase."( Effects of a new benzodiazepine derivative cholecystokinin receptor antagonist FK480 on pancreatic exocrine secretion in anesthetized rats.
Otsuki, M; Tachibana, I, 1994
)
0.29
" Our results suggest that adaptation of physiological mechanisms governing the exocrine pancreas may occur after one week of receptor blockade by a therapeutic dosage of telenzepine, to the extent that M1-blockade no longer inhibits secretion."( Exocrine pancreatic secretion in man following one week of M1-muscarinic receptor blockade.
Ditschuneit, H; Glasbrenner, B; Kemmer, TP; Malfertheiner, P; Nelson, DK; Schneider, A, 1993
)
0.29
" First, a dose-response curve of ceruletid was obtained in 20 mechanically ventilated patients of a surgical intensive care unit (SICU) not receiving enteral nutrition."( Influence of ceruletid on gallbladder contraction: a possible prophylaxis of acute acalculous cholecystitis in intensive care patients?
al-Bazaz, B; Gotzen, L; Hasse, C; Nies, C; Rothmund, M; Zielke, A, 1995
)
0.29
" In further experiments we determined the time course and the minimal dosage required for the induction of this severe and non-invasive disease variety."( Characterization of a non-invasive, vascular model of acute necrotizing pancreatitis.
Adler, G; Gress, TM; Lerch, MM; Schoenberg, MH; Turi, S; Weidenbach, H, 1996
)
0.29
"h-1) evoked a characteristic biphasic dose-response curve for pancreatic juice and protein output in the LETO rats, whereas the OLETF rats were totally insensitive to CCK-8 stimulation."( Defect in pancreatic exocrine and endocrine response to CCK in genetically diabetic OLETF rats.
Akiyama, T; Furumi, K; Kanagawa, K; Otsuki, M; Shiohara, H; Tachibana, I; Watanabe, N, 1996
)
0.29
" Acinar cell morphology and function remained intact as demonstrated by electron microscopy and secretagogue dose-response studies."( Elevated calcium and activation of trypsinogen in rat pancreatic acini.
Bimmler, D; Fernández-del Castillo, C; Frick, TW; Warshaw, AL, 1997
)
0.3
" Kinase II inhibitor captopril or exogenous bradykinin in addition to an otherwise effective dosage of icatibant resulted in microcirculatory stasis, extensive venular leukocyte adherence, and severe histological damage."( Inhibition of bradykinin B2 receptor preserves microcirculation in experimental pancreatitis in rats.
Bloechle, C; Izbicki, JR; Knoefel, WT; Kuehn, RM; Kusterer, K; Schneider, C, 1998
)
0.3
" administration of cerulein and WGA or UEA in a dosage of 125 microg/kg/h for 8 h led to a reduction of vacuolar diameter from 13."( Morphometric measurements to quantify the cerulein induced hyperstimulatory pancreatitis of rats under the protective effect of lectins.
Beckmann, U; Dölker, K; Hahnel, C; Jonas, L; Kundt, G; Mikkat, U; Nizze, H; Weber, H; Witte, A, 1998
)
0.3
" After recovery, in both sets of dogs, dose-response studies of the pancreatic secretory response to intraileal infusion with graded loads of tryptophan (0."( Pancreatic secretory response to intraileal amino acids: studies in dogs with an in situ neurally isolated ileum.
Niebel, W; Niebergall-Roth, E; Singer, MV; Teyssen, S, 2000
)
0.31
"Supramaximal dosage of the cholecystokinin analog caerulein leads to edematous pancreatitis with subsequent acinar cell destruction predominantly by apoptosis."( Expression of galectin-3 in the rat pancreas during regeneration following hormone-induced pancreatitis.
Ackermann, W; Elsässer, HP; Gebhardt, A; Unver, N, 2004
)
0.32
" The effects of cerulein exhibited the dose-response character."( Regional differences in the effects of various doses of cerulein upon the small-intestinal migrating motor complex in fasted and non-fasted sheep.
Romański, KW, 2007
)
0.34
" In conclusion, subcutaneously administrated cerulein in dosage of 5 and 10 μg/kg resulted in AP in rats, with significant changes in red blood cell deformability and alterations in erythrocyte aggregation."( Micro-rheological changes during experimental acute pancreatitis in the rat.
Furka, I; Kiss, F; Kotan, R; Miko, I; Miszti-Blasius, K; Nemeth, N; Posan, J; Sapy, P; Szentkereszty, Z; Toth, L, 2012
)
0.38
" Amylase release from pancreas tissue slices decreased during culture, but maintained the characteristic bell-shaped dose-response curve to increasing caerulein concentrations and a ca."( Mouse pancreas tissue slice culture facilitates long-term studies of exocrine and endocrine cell physiology in situ.
Friedrich, B; Marciniak, A; Selck, C; Speier, S, 2013
)
0.39
"When SAP mouse models were treated with ulinastatin at a dosage of 50,000 U/kg body weight, we found, through biochemical and histopathological analyses, that the pancreatic injury was significantly ameliorated."( Ulinastatin activates the renin-angiotensin system to ameliorate the pathophysiology of severe acute pancreatitis.
Cui, L; Liu, R; Qi, H; Wang, J; Wang, Y; Wen, Y; Yin, C, 2014
)
0.4
" Since chronic administration of high doses of antioxidants may have deleterious effects, dosage levels and duration of antioxidant treatment should be carefully determined."( Oxidative stress and inflammatory signaling in cerulein pancreatitis.
Kim, H; Yu, JH, 2014
)
0.4
"MS (16ml/kg) was administered at different dosing frequencies on mice with cerulein-induced AP."( Methane-rich saline alleviates cerulein-induced acute pancreatitis by inhibiting inflammatory response, oxidative stress and pancreatic apoptosis in mice.
Deng, X; Fa, Z; Fei, M; Wang, J; Wang, L; Xie, Q; Zhang, Y, 2017
)
0.46
" Control animals were dosed with phosphate-buffered saline at corresponding volumes and intervals."( Detection of Reg3γ by Immunohistochemistry in Cerulein-Induced Model of Acute Pancreatic Injury in Mice and Rats.
Rouse, R; Shea, K, 2019
)
0.51
"Reg3γ staining quantified through image analysis showed a time- and dose-response in cerulein-treated mice and rats."( Detection of Reg3γ by Immunohistochemistry in Cerulein-Induced Model of Acute Pancreatic Injury in Mice and Rats.
Rouse, R; Shea, K, 2019
)
0.51
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
diagnostic agentA substance administered to aid diagnosis of a disease.
gastrointestinal drugA drug used for its effects on the gastrointestinal system, e.g. controlling gastric acidity, regulating gastrointestinal motility and water flow, and improving digestion.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
oligopeptideA peptide containing a relatively small number of amino acids.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (2,851)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990973 (34.13)18.7374
1990's687 (24.10)18.2507
2000's486 (17.05)29.6817
2010's501 (17.57)24.3611
2020's204 (7.16)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 44.07

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index44.07 (24.57)
Research Supply Index8.04 (2.92)
Research Growth Index4.51 (4.65)
Search Engine Demand Index72.26 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (44.07)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials91 (3.03%)5.53%
Reviews63 (2.10%)6.00%
Case Studies19 (0.63%)4.05%
Observational1 (0.03%)0.25%
Other2,828 (94.20%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]